UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 15.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 219,125 shares of the biopharmaceutical company's stock after buying an additional 29,386 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.13% of ACADIA Pharmaceuticals worth $4,021,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Barclays PLC raised its position in shares of ACADIA Pharmaceuticals by 126.2% during the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock valued at $4,269,000 after purchasing an additional 154,854 shares during the period. KBC Group NV raised its holdings in ACADIA Pharmaceuticals by 67.0% during the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 2,044 shares during the period. Principal Financial Group Inc. raised its holdings in ACADIA Pharmaceuticals by 10.9% during the fourth quarter. Principal Financial Group Inc. now owns 143,694 shares of the biopharmaceutical company's stock valued at $2,637,000 after acquiring an additional 14,143 shares during the period. New York State Common Retirement Fund lifted its position in shares of ACADIA Pharmaceuticals by 14.0% in the fourth quarter. New York State Common Retirement Fund now owns 51,374 shares of the biopharmaceutical company's stock valued at $943,000 after acquiring an additional 6,310 shares in the last quarter. Finally, Handelsbanken Fonder AB boosted its stake in shares of ACADIA Pharmaceuticals by 15.1% in the fourth quarter. Handelsbanken Fonder AB now owns 54,833 shares of the biopharmaceutical company's stock worth $1,006,000 after acquiring an additional 7,200 shares during the period. 96.71% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at ACADIA Pharmaceuticals

In related news, EVP Mark C. Schneyer sold 2,708 shares of the firm's stock in a transaction that occurred on Tuesday, April 8th. The stock was sold at an average price of $14.82, for a total transaction of $40,132.56. Following the completion of the sale, the executive vice president now directly owns 59,456 shares of the company's stock, valued at approximately $881,137.92. This trade represents a 4.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James Kihara sold 4,000 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $22.50, for a total value of $90,000.00. Following the transaction, the insider now owns 20,395 shares of the company's stock, valued at approximately $458,887.50. The trade was a 16.40% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,273 shares of company stock worth $653,182 over the last quarter. Insiders own 26.50% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on ACAD. Wall Street Zen raised ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Wednesday, May 21st. Cantor Fitzgerald upgraded shares of ACADIA Pharmaceuticals to a "strong-buy" rating in a research report on Thursday. Bank of America boosted their target price on shares of ACADIA Pharmaceuticals from $18.00 to $23.00 and gave the stock a "hold" rating in a report on Thursday. Morgan Stanley set a $24.00 price target on shares of ACADIA Pharmaceuticals and gave the company an "equal weight" rating in a report on Tuesday, May 20th. Finally, Needham & Company LLC boosted their price target on shares of ACADIA Pharmaceuticals from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday, May 19th. Six investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $26.79.

ACADIA Pharmaceuticals Stock Up 3.0%

NASDAQ ACAD traded up $0.64 during trading hours on Friday, hitting $21.98. 1,280,062 shares of the company were exchanged, compared to its average volume of 1,934,088. ACADIA Pharmaceuticals Inc. has a 52 week low of $13.40 and a 52 week high of $25.23. The stock has a 50-day moving average price of $17.24 and a 200 day moving average price of $17.60. The stock has a market cap of $3.68 billion, a PE ratio of 28.18 and a beta of 0.47.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.01. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The firm had revenue of $244.32 million for the quarter, compared to the consensus estimate of $239.32 million. During the same quarter in the previous year, the company posted $0.10 EPS. The company's revenue for the quarter was up 18.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current year.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.